Omeros Corporation was founded in 1992 and is headquartered in Seattle, Washington. Under the leadership of CEO Dr. Gregory A. Demopulos, the company has focused on drug candidates that modulate the complement system and other inflammatory pathways, especially in rare, high-unmet-need indications.

The current strategy is anchored on:

• Complement pathway targeting: MASP-2 (narsoplimab), MASP-3 (Zaltenibart, now partnered with Novo Nordisk), and additional preclinical programs in the lectin and alternative pathways.
• Orphan and specialty indications: TA-TMA post-transplant, IgA nephropathy, paroxysmal nocturnal hemoglobinuria (via Novo Nordisk on Zaltenibart), and related rare blood and kidney disorders.
• Economics: focus on settings where high morbidity and mortality justify premium pricing, favourable reimbursement and potentially strong margins if a drug is approved.

Before the Novo deal, Omeros was viewed as financially constrained, with a limited cash runway and meaningful debt. The recent licensing agreement fundamentally changes that picture and gives the company room to operate into and beyond the narsoplimab decision.

Disease background – TA-TMA after hematopoietic stem-cell transplant

Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication that can occur after hematopoietic stem-cell transplantation. It is characterised by microvascular thrombosis, hemolytic anaemia, thrombocytopenia and multi-organ involvement, including renal and neurological damage. Historically, mortality for high-risk TA-TMA has been reported in the range of 60–90 percent, especially when diagnosis is delayed or treatment is purely supportive.

There is currently no FDA-approved therapy specifically indicated for TA-TMA. Management largely relies on:

• Supportive care (transfusions, blood-pressure control, renal support).
• Adjustment of immunosuppressive regimens.
• Occasional off-label use of broader complement inhibitors, without a labelled indication.

Mechanism of action – MASP-2 and the lectin pathway

Narsoplimab is a fully human monoclonal antibody against MASP-2 (mannan-binding lectin-associated serine protease-2), a key protease in the lectin pathway of complement activation. By inhibiting MASP-2, narsoplimab aims to:

• Prevent downstream complement activation and microvascular damage in TA-TMA.
• Leave the classical complement pathway relatively intact, in theory preserving important anti-infective functions.

This more selective targeting differentiates narsoplimab from agents that fully block terminal complement (such as C5 inhibitors), potentially providing a better tolerability balance in heavily immunocompromised transplant patients.

Clinical evidence – pivotal and expanded access data

Omeros’ case with the FDA rests on two main pillars:

Overall, the evidence package provides the FDA with two convergent lines of data (pivotal trial and EAP) showing improved survival in a population with otherwise devastating outcomes, using an external-control framework that is relatively common in rare diseases where randomised trials are difficult.

Regulatory trajectory and current positioning

Key regulatory milestones so far:

• Initial BLA rejected in 2021, with FDA flagging concerns about data robustness and external control use.
• In March 2025, Omeros resubmitted a revised BLA incorporating additional analyses and expanded access data; FDA accepted the filing with a PDUFA date of September 25, 2025.
• Following further information requests, the FDA extended the PDUFA date to December 26, 2025, noting that, if no major deficiencies emerged, label discussions would begin no later than October 2025.
• Omeros has publicly stated that all analyses requested by FDA continue to support narsoplimab’s benefit in TA-TMA.

For investors, the tone of communication is key. The extension itself is not unusual for rare disease filings; the important point is that, as of the latest company and regulatory updates, there is no explicit signal of a major unresolved deficiency. That does not remove risk, but it supports the case that an approval or at least an “approvable” outcome is plausible.

Before the Novo Nordisk agreement, Omeros’ financial situation was fragile. As of September 30, 2025, the company reported roughly 36 million USD in cash and short-term investments and a quarterly cash burn of about 22 million USD, with meaningful debt on the balance sheet. That translated into a limited runway and clear concern about potential dilution if narsoplimab was delayed or rejected.

The Novo Nordisk deal, announced in October and closed on December 1, 2025, changed that picture:

• Upfront and near-term milestones: up to 340 million USD, of which 240 million USD is upfront cash at closing for global rights to Zaltenibart (MASP-3 antibody) in PNH and other indications.
• Total potential value: up to 2.1 billion USD including development, regulatory and commercial milestones plus tiered royalties on net sales.
• Use of proceeds: repayment of the 67 million USD term loan and a substantial portion of the 2026 notes, materially reducing debt and interest burden.
• Runway: management now expects a multi-year operating runway, even in the absence of narsoplimab revenue, which is a very different risk profile from early 2025.

From a balance-sheet standpoint, Omeros enters the PDUFA window in a far stronger position: cash is no longer the immediate concern. The combination of the Novo cash and potential orphan revenue from TA-TMA is central to the bullish thesis on OMER.

Price action and volatility

• Over the last 12 months, OMER has traded between roughly 2.95 and 13.60 USD, with pronounced spikes around regulatory and deal headlines.
• The stock surged sharply in October 2025 on the Novo Nordisk deal announcement, more than doubling intraday as investors repriced the balance sheet improvement and strategic validation.
• Since then, OMER has retraced and stabilised in the high single-digit range, as the market digests the deal and turns attention back to the narsoplimab PDUFA catalyst.
• Technical services now classify the stock as high-risk, high-volatility, with daily swings frequently in the 8–11 percent range as traders position into the decision.

Street and retail sentiment

• Analyst coverage is limited but tilts positive: available data points show an average 12-month target around 28 USD with a range of roughly 20–36 USD, and an overall rating of Buy.
• On retail and social platforms (Stocktwits, Reddit, X), sentiment is polarised:
  • One camp focuses on the peer-reviewed survival data, the Novo deal and the lack of any approved TA-TMA therapy, making a strong case for approval and upside.
  • The other camp highlights the painful history of the 2021 rejection, the small trial size and the inherent danger of betting heavily on binary events.
• Short-term flows reflect typical catalyst risk positioning: some traders taking profits into strength, others building speculative positions expecting a sharp move after the FDA decision.

All sentiment references here relate to non-professional traders and public commentary. They are useful to understand crowd psychology and positioning but are not a substitute for independent due diligence.

1. December 26, 2025: FDA PDUFA decision for narsoplimab in TA-TMA (binary event).
2. Late December 2025 – January 2026: Market reaction and first commentary on label terms, safety language and scope of approved indication (if approval is granted).
3. Q1–Q2 2026: Launch preparation and early commercial uptake indicators in U.S. transplant centers; initial commentary from clinicians and payers.
4. Mid-2026: Potential European Medicines Agency (EMA) committee opinion on narsoplimab for TA-TMA.
5. 2026–2027: Updates on IgA nephropathy development and Novo Nordisk’s Zaltenibart program in PNH and related conditions, both of which could reinforce the broader complement platform story.
6. 2027 and beyond: Potential guidance on full-year narsoplimab revenues and any move towards profitability if orphan launches perform as expected.